FDA approves expanded Camzyos label for Bristol Myers Squibb to treat obstructive HCM in patients weighing 30 kg or more
Bitget2026/09/30 21:32- FDA cleared an expanded label for Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy in adults.
- Decision adds pediatric patients weighing 30 kg or more, making Camzyos the only FDA-approved oHCM therapy for children.
- Approval backed by Phase 3 SCOUT-HCM data showing a 48 mmHg greater reduction in Valsalva LVOT gradient versus placebo at week 28.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Mortgage rates return to 7%, pending home sales in the US fall to nearly a twelve-year low
According to Freddie Mac data, the 30-year fixed mortgage rate has risen to 7.4%, the highest level in nearly three years. Data from real estate brokerage Redfin shows that the volume of existing home pending sales in September fell 4% month-on-month, marking the largest single-month drop in over three years and hitting the lowest level since 2014. Nearly one-fifth of sellers have reduced prices, and the home purchase contract cancellation rate has reached a record high of 14.5%. Inventory levels have risen to the highest since March 2020, but high financing costs continue to constrain transactions.
Mueller Water Products names Michael Morgan CFO, succeeding Melissa Rasmussen
GLD ETF Falls 0.6%
JPMorgan’s tokenized funds on Ethereum hold $844 million
Crypto prices
More
